Emerging research highlights important differences among diabetes therapies in their potential to reduce the risk of Alzheimer’s disease (AD), a condition increasingly linked to type 2 diabetes. Using an integrative network pharmacology framework, investigators compared 39 diabetes treatments to evaluate their influence on shared molecular pathways between diabetes and neurodegeneration. The analysis revealed that metformin demonstrated the strongest potential for neuroprotection, primarily through modulation of key pathways such as AMPK activation, insulin signaling, and adipocytokine regulation, mechanisms known to influence inflammation, metabolism, and neuronal survival. In contrast, semaglutide, despite its widespread use in glycemic control and weight management, showed relatively limited interaction with core Alzheimer’s-related biological pathways in this comparative model.

Interestingly, certain combination therapies such as insulin glargine with lixisenatide and insulin degludec with liraglutide displayed neuroprotective effects comparable to metformin. These findings suggest that diabetes treatments may differ substantially in their ability to influence long-term cognitive outcomes. The results support prioritizing metformin for further clinical investigation in individuals with diabetes at high risk of cognitive decline. More broadly, the study underscores the growing importance of precision medicine approaches in selecting diabetes therapies that not only optimize metabolic control but may also confer additional benefits for brain health and Alzheimer’s disease prevention.

Read More